ClinicalTrials.gg
CompletedNCT06399315Updated Dec 9, 2025

Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers

A Phase 1 interventional study of ZE46-0134 or placebo and Rabeprazole, 20mg oral in AML, sponsored by Lomond Therapeutics Holdings, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by Lomond Therapeutics Holdings, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jul 2023, registered May 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a clinical study aiming to assess pharmacokinetics and biomarker evidence of ZE46-0134 efficacy in Healthy Volunteers after single and multiple daily doses of the study drug

Read the detailed description

This is a Phase 1, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, PK, PD of orally administered ZE46-0134 in Healthy Volunteers. The study will be conducted in 2 parts: a single ascending dose (SAD) part at up to 6 dose levels and a multiple ascending dose (MAD) part at up to 5 dose levels. Evaluation of dose levels will be conducted in a sequential fashion with lower dose levels evaluated first in the sequence. Dosing in each cohort will start with two sentinel participants with one of the two sentinels randomised to receive ZE46-0134 and the other randomised to receive placebo. The food-effect will be investigated in SAD part and safety/PK of co-administration with rabeprazole will be investigated in MAD part.

02

Conditions studied

  • AML
03

In context

Lead sponsor

Lomond Therapeutics Holdings, Inc. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Must have given written before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.

    2. Adult males and females, 18 to 55 years of age (inclusive) at screening. 3. (BMI) ≥ 18.5 and ≤ 32.0 kg/m2, with a body weight (to 1 decimal place) ≥ 50.0 kg at screening.

    4. Medically healthy without abnormalities (in the opinion of the Investigator) at the screening visit and prior to dosing

Exclusion criteria

Exclusion Criteria:

  1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or major surgery within the past 3 months determined by the PI to be .
  2. Acute infections within 4 weeks prior to screening or current infection that requires systemically absorbed antibiotic, antifungal, antiparasitic or antiviral medications.
  3. Presence or history of any abnormality or illness, including gastrointestinal surgery, which in the opinion of the PI may affect absorption, distribution, metabolism or elimination of the study drug.
  4. Any history of malignant disease in the last 5 years (excludes surgically resected skin squamous cell or basal cell carcinoma).
  5. Any screening laboratory result outside the normal laboratory reference range (as confirmed upon repeated testing) and deemed clinically significant by the PI.
  6. Presence of clinically relevant from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Level 1 Single dose

    Dose level 1. SAD study part. 6 participants will receive the study drug and 2 participants will receive placebo

    Drug: ZE46-0134 or placebo

  • Experimental
    Level 2 Single dose

    Dose level 2. SAD study part. 6 participants will receive the study drug and 2 participants will receive placebo

    Drug: ZE46-0134 or placebo

  • Experimental
    Level 3 Single dose

    Dose level 3. SAD study part. 6 participants will receive the study drug and 2 participants will receive placebo

    Drug: ZE46-0134 or placebo

  • Experimental
    Level 2 Single dose after food

    Dose level 2 with a fat meal. SAD study part. 6 participants will receive the study drug and 2 participants will receive placebo

    Drug: ZE46-0134 or placebo

  • Experimental
    Level 4 Single dose

    Dose level 4. SAD study part. 6 participants will receive the study drug and 2 participants will receive placebo

    Drug: ZE46-0134 or placebo

  • Experimental
    Level 1 Multiple doses

    Dose level 1. MAD study part. 6 participants will receive the study drug and 2 participants will receive placebo

    Drug: ZE46-0134 or placebo

  • Experimental
    Level 1 Multiple doses + rabeprazole

    Dose level 2. MAD study part. 6 participants will receive the study drug and 2 participants will receive placebo. The drug is co-administered with rabeprazole

    Drug: ZE46-0134 or placebo · Drug: Rabeprazole, 20mg oral

  • Experimental
    Level 2 Multiple doses

    Dose level 2. MAD study part. 6 participants will receive the study drug and 2 participants will receive placebo

    Drug: ZE46-0134 or placebo

  • Experimental
    Level 3 Single dose with itraconazole

    Dose level 3. SAD study part. 6 participants will receive the study drug and 2 participants will receive placebo, in conjunction with itraconazole

    Drug: ZE46-0134 or placebo · Drug: Itraconazole (200 mg)

  • Experimental
    Level 5 Single dose

    Dose level 5. SAD study part. 6 participants will receive the study drug and 2 participants will receive placebo

    Drug: ZE46-0134 or placebo

  • Experimental
    Level 6 Single dose

    Dose level 6. SAD study part. 6 participants will receive the study drug and 2 participants will receive placebo

    Drug: ZE46-0134 or placebo

  • Experimental
    Level 3 Multiple doses

    Dose level 3. MAD study part. 6 participants will receive the study drug and 2 participants will receive placebo

    Drug: ZE46-0134 or placebo

  • Experimental
    Level 4 Multiple doses

    Dose level 4. MAD study part. 6 participants will receive the study drug and 2 participants will receive placebo

    Drug: ZE46-0134 or placebo

  • Experimental
    Level 5 Multiple doses

    Dose level 5. MAD study part. 6 participants will receive the study drug and 2 participants will receive placebo

    Drug: ZE46-0134 or placebo

Interventions

  • DrugZE46-0134 or placebo

    The patients will receive ZE46-0134 or placebo

    Also known as: lomonitininb

  • Rabeprazole 20 mg daily will be administered for 2 prior ZE46-0134 and 7 co-administered

  • Itraconazole 200 mg BID

06

What researchers measure

Primary outcomes

  1. Plasma concentration

    Plasma concentration, ng/mL

    Time frame: 72 hours for SAD, 10 days for MAD

Secondary outcomes

  1. Incidence of AEs

    Incidence of Adverse Events observed during the study

    Time frame: 8 days in SAD part, 17 days for MAD part

  2. Incidence of drug-related AEs

    Incidence of Adverse Events observed during the study deemed related to the study drug by the Investigator

    Time frame: 8 days in SAD part, 17 days for MAD part

  3. Incidence of SAEs

    Incidence of Serious Adverse Events observed during the study

    Time frame: 8 days in SAD part, 17 days for MAD part

  4. Incidence of lab deviations

    Incidence of clinically relevant deviations in the clinical laboratory parameters

    Time frame: Time Frame: 8 days in SAD part, 17 days for MAD part

07

Study locations

1 site
  • Linear Clinical Research Ltd
    Perth, Nedlands WA 6009, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Jun 2025, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2024
First posted
May 3, 2024
StartActual
Jul 28, 2023
Primary completionActual
Jun 30, 2025
CompletionActual
Aug 26, 2025
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06399315
Lead sponsor
Lomond Therapeutics Holdings, Inc.
Responsible party
Sponsor
First posted
May 3, 2024
Start date
Jul 28, 2023
Primary completion
Jun 30, 2025
Completion
Aug 26, 2025
Last update
Dec 9, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rabeprazole · Itraconazole

Start the discussion